Literature DB >> 6705427

Ultrafiltration vs equilibrium dialysis for determination of free fraction.

W F Bowers, S Fulton, J Thompson.   

Abstract

The analytical basis of membrane separation in determining plasma free drug concentrations is developed from consideration of the generalised ideal mass action and conservation laws applied to thermodynamic states of differing component volumes. The intuitively surprising theoretical independence of free drug concentration with changing fractional volume of protein predicts the equivalence of final free drug concentration after uniform pre-dilution with that after equilibrium dialysis against the same volume of buffer. Similarly, the ultrafiltrate free concentration of drugs in ideal plasma binding equilibrium is theoretically constant, regardless of the extent of reduction in fractional volume of binding protein during filtration. The pitfalls in calculating free and bound fraction and concentration from equilibrium dialysis are reviewed and expressions presented to correct the major artefacts. The dilution behaviour of drugs is predicted from the normalised mass action model. Practical aspects of validating ultrafiltration free drug levels using equilibrium dialysis are outlined.

Mesh:

Substances:

Year:  1984        PMID: 6705427     DOI: 10.2165/00003088-198400091-00007

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  32 in total

1.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

2.  Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration.

Authors:  H Kurz; H Trunk; B Weitz
Journal:  Arzneimittelforschung       Date:  1977-07

3.  Potential methodological errors in the application of equilibrium dialysis to the determination of "free" and "bound" plasma tryptophan.

Authors:  C Chadwick; D A Phipps; C Powell
Journal:  Clin Chim Acta       Date:  1979-12-17       Impact factor: 3.786

4.  Difficulties in applying the Scatchard model of ligand binding to proteins--proposal of new mathematical tools--application to salicylates.

Authors:  C Monot; P Netter; M C Stalars; J Martin; R J Royer; A Gaucher
Journal:  J Pharm Sci       Date:  1983-01       Impact factor: 3.534

5.  Symbols in pharmacokinetics.

Authors:  M Rowland; G Tucker
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

6.  The "ultra-free" ultrafiltration technique compared with equilibrium dialysis for determination of unbound thiopental concentrations in serum.

Authors:  D Jung; M Mayersohn; D Perrier
Journal:  Clin Chem       Date:  1981-01       Impact factor: 8.327

7.  Effect of initial conditions and drug-protein binding on the time to equilibrium in dialysis systems.

Authors:  P J McNamara; J B Bogardus
Journal:  J Pharm Sci       Date:  1982-09       Impact factor: 3.534

8.  New aspects of free drug concentration determination in human serum with equilibrium dialysis.

Authors:  W F van der Giesen; J Wilting
Journal:  Methods Find Exp Clin Pharmacol       Date:  1982 Aug-Sep

9.  Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum.

Authors:  J W Paxton; R A Donald
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

10.  Phenytoin binding to human albumin.

Authors:  M Lecomte; R Zini; P d'Athis; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

View more
  13 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

3.  Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model.

Authors:  C Padoin; M Tod; G Perret; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 4.  Methods for measuring aptamer-protein equilibria: a review.

Authors:  Meng Jing; Michael T Bowser
Journal:  Anal Chim Acta       Date:  2010-11-10       Impact factor: 6.558

5.  Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats.

Authors:  A Jacolot; M Tod; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

6.  In vitro protein binding of propafenone in normal and uraemic human sera.

Authors:  G L Chan; J E Axelson; J D Price; K M McErlane; C R Kerr
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

8.  Simultaneous determination and validation of oncrasin-266 and its metabolites by HPLC-MS/MS: Application to a pharmacokinetic study.

Authors:  Lyndsey White; Shuhong Wu; Jing Ma; Bingliang Fang; Dong Liang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-08-10       Impact factor: 3.205

9.  Evaluation of Quantitative Structure Property Relationship Algorithms for Predicting Plasma Protein Binding in Humans.

Authors:  Yejin Esther Yun; Rogelio Tornero-Velez; S Thomas Purucker; Daniel T Chang; Andrea N Edginton
Journal:  Comput Toxicol       Date:  2021-02-01

10.  Microdialysis: an alternative for in vitro and in vivo protein binding studies.

Authors:  A Le Quellec; S Dupin; A E Tufenkji; P Genissel; G Houin
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.